Earli

Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.

Earli headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Oncology sector. The company focuses on Biotechnology and has secured $2.9B in funding across 48 round(s). With a team of 11-50 employees, Earli is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Earli, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.